Scientific Presentations for Products in Development

Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links.

To view Encore Presentations, visit our Encore Presentations Page.

Clinical Activity of Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and <i>BRCA1</i> or <i>BRCA2</i> Mutations Identified by FoundationOne® Liquid CDx (F1L CDx)

Virtual Presentation 2020 PCF Scientific Retreat

Initial clinical experience of lucitanib + nivolumab in advanced metastatic solid tumours: data from the phase 1b/2 LIO-1 study (CO-3810-101; NCT04042116)

Poster Presentation 2020 ESMO Virtual Meeting

LIO-1: A Phase 2 study of lucitanib + nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO)

Poster Presentation 2020 ESMO Virtual Meeting

Timing of adverse events during maintenance treatment with rucaparib for recurrent ovarian cancer in the phase 3 ARIEL3 study

Poster Presentation 2020 ESMO Virtual Meeting

Rucaparib population pharmacokinetics and exposure-response analyses in patients with metastatic castration-resistant prostate cancer (mCRPC) in TRITON2

Poster Presentation 2020 ESMO Virtual Meeting

Rucaparib + sacituzumab govitecan: initial data from the phase 1b/2 SEASTAR study (NCT03992131)

Poster Presentation 2020 ESMO Virtual Meeting

Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy to fibroblast activation protein alpha

Poster Presentation 2020 ESMO Virtual Meeting

Postprogression Efficacy Outcomes From the Phase 3 ARIEL3 Study of Rucaparib in Patients With Platinum-Sensitive Recurrent Ovarian Carcinoma Associated With Either <i>BRCA1</i> or <i>BRCA2</i> Mutations

Virtual Presentation 2020 ICGS Digital Annual Global Meeting

Evaluation of Brain Pharmacokinetics (PK) and Tumor Growth Inhibition of PARP Inhibitors in Mouse Xenograft Models Using Semi-Mechanistic PK/Pharmacodynamic (PD) Modeling

Poster Presentation 2020 AACR Virtual Meeting II

Application of Machine Learning and Grid Search Approaches to Minimize Lucitanib Pharmacokinetic Variability Following Different Dosing Regimens

Poster Presentation 2020 AACR Virtual Meeting II

The Combination of a Mouse Ortholog of ALKS 4230, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, and the Angiogenesis Inhibitor Lucitanib Enhances Antitumor Activity

Poster Presentation 2020 AACR Virtual Meeting II

Characterization of Patients With Long-term Responses to Rucaparib in Recurrent Ovarian Cancer

Virtual Presentation 2020 ASCO

Postprogression Outcomes in Patients With Ovarian Carcinoma Associated With a Mutation in a Non-<i>BRCA</i> Homologous Recombination Repair Gene Receiving Rucaparib Maintenance Treatment: Results From the Phase 3 Study ARIEL3

Webinar Presentation 2020 SGO

Population Exposure-Safety and Exposure-Efficacy Analyses for Rucaparib in Patients With Recurrent Ovarian Carcinoma From Study 10 and ARIEL2

Poster Presentation 2020 SGO

Rucaparib for recurrent, locally advanced or metastatic urothelial carcinoma: results from ATLAS, a phase 2, open-label trial

Presented at 2020 ASCO GU

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with <i>BRCA1</i> or <i>BRCA2</i> (<i>BRCA</i>)-mutated metastatic castration-resistant prostate cancer (mCRPC)

Presented at 2020 ASCO GU

Combination of the Angiogenesis Inhibitor Lucitanib with Immune Checkpoint Blockade Augments Anti-tumor Activity in Syngeneic Models

Presented at 2019 SITC

ATHENA (GOG-3020/ENGOT-ov45): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitor Rucaparib + the PD-1 Inhibitor Nivolumab Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer

Presented at 2019 ASGO